Q3 2025 13F Holders as of 30 Sep 2025
-
Type / Class
-
Equity / Common Shares, without par value
-
Shares outstanding
-
193M
-
Number of holders
-
166
-
Total 13F shares, excl. options
-
118M
-
Shares change
-
+25.1K
-
Total reported value, excl. options
-
$536M
-
Value change
-
+$2.49M
-
Put/Call ratio
-
0.27
-
Number of buys
-
70
-
Number of sells
-
-70
-
Price
-
$4.54
Significant Holders of Arbutus Biopharma Corp - Common Shares, without par value (ABUS) as of Q3 2025
199 filings reported holding ABUS - Arbutus Biopharma Corp - Common Shares, without par value as of Q3 2025.
Arbutus Biopharma Corp - Common Shares, without par value (ABUS) has 166 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 118M shares
of 193M outstanding shares and own 61.1% of the company stock.
Largest 10 shareholders include MORGAN STANLEY (24.5M shares), Whitefort Capital Management, LP (13.3M shares), BlackRock, Inc. (12.7M shares), Two Seas Capital LP (11M shares), VANGUARD GROUP INC (8.99M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (5.01M shares), STATE STREET CORP (4.1M shares), GEODE CAPITAL MANAGEMENT, LLC (3.67M shares), ADAR1 Capital Management, LLC (2.9M shares), and GOLDMAN SACHS GROUP INC (2.17M shares).
This table shows the top 166 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.